With fin­ish line in sight, Brig­gs Mor­ri­son steps aside from Syn­dax CEO seat, swaps role with long­time col­league

More than six years af­ter leav­ing the top med­ical role at As­traZeneca to test his hand at be­ing a biotech CEO, Brig­gs Mor­ri­son de­cid­ed he’s more at home in an R&D role af­ter all.

Syn­dax Phar­ma­ceu­ti­cals, the Waltham, MA-based can­cer spe­cial­ist he’s been helm­ing, an­nounced that Mor­ri­son will be tran­si­tion­ing to the new role of pres­i­dent, head of R&D to make room for Michael Met­zger, the cur­rent pres­i­dent and COO, to as­sume the CEO post.

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER